Context

Abiraterone (Zytiga® by Janssen/J&J) and enzalutamide (Xtandi® by the Astellas group), two hormone therapy agents targeting androgen receptor (AR) signaling, have been used effectively in clinical trials and have been made available to medical professionals to treat metastatic castration-resistant prostate cancer. Unfortunately, resistance to these drugs develops very commonly after one to two years.

Benefits

Combining a MAP Kinase p38 inhibitor with abiraterone or enzalutamide should create a powerful synergy effect that would reduce the proliferation of prostate cancer cells.

Applications

Prostate cancer